Portola Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Millennium Pharmaceuticals Limited

Alexion Pharmaceuticals, Inc.

Epitherapeutics Aps

Mukund Mehrotra

Anjali Pandey

Yonghong Song

Qing Xu

Shawn M Bauer

Wolin Huang

Zhaozhong Jon Jia

Jack W Rose

Chandrasekar Venkataramani

Brian Kane

Thomas Boesen

Marc A Labelle

Farman Ullah

Qasim Khan

Robert M Scarborough

Ramkrishna Reddy Vakiti

Neerja Saraswat

Ying Yang

Utpal Sharma

Xiaoming Zhang

Uma Sinha

David R Phillips

Patrick Andre

Pamela B Conley

Craig Grant

Carroll Scarborough, Legal Representative

Hilary Cannon

Craig M Grant

The present invention is directed to methods of treating multiple myeloma by administering a compound of Formula (I) or pharmaceutically acceptable salt thereof.

Inhibitors of protein kinases

The present invention is directed to topical pharmaceutical compositions of Formula (If) or pharmaceutically acceptable salt thereof, which act as inhibitors of syk and/or JAK kinase activity. The described topical pharmaceutical compositions are useful in preventing or treating a number of conditions mediated at least in part by syk and/or JAK kinase activity.

The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form 

Inhibitors of histone demethylases

Compounds of the form In which Q is selected from &#x2014;CH&#x2550;NR, &#x2014;W, &#x2014;CHNHR, &#x2014;CH&#x2550;O and &#x2014;CH(OR)capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.

The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

Inhibitors of syk and JAK protein kinases

The present invention is directed to compounds of formula I-II and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

Nicotinamides as JAK kinase modulators

The present invention is directed to compounds of formula I and tautomers and pharmaceutically acceptable salts thereof which are selective inhibitors of JAK. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK activity, and methods to prevent or treat a number of conditions mediated at least in part by JAK activity.

Inhibitors of JAK

The present invention is directed to a compound of the formula: and pharmaceutically acceptable tautomers, or salts thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to pharmaceutical compositions containing such a compound.

Inhibitors of SYK and JAK protein kinases

Growing community of inventors

South San Francisco, CA, United States of America

Mukund Mehrotra